| 영문 | complement | 한글 | 보체 |
|---|---|---|---|
| 설명 | 항체와 반응하여 항체와 결합된 세포의 파괴를 일으키는 단백질을 말한다. 항체가 항체와 결합한 세포를 파괴하는 방법에는 여러 가지가 있는데 그 중의 하나로 항체와 결합한 세포의 표면을 부분적으로 손상시켜 그 세포를 파괴하는 역할을 하는 것이 이 보체이다. 보체는 20가지의 단백질로 구성되어 있는데 약자로 C로 표시하며 각 종류를 나타낼 경우에는 C옆에 숫자를 써서 표시한다. |
||
| 영문 | complement fixation reaction | 한글 | 보체결합 반응, 도움체결합반응 |
|---|---|---|---|
| 설명 | 항체와의 반응에 있어서 보체와 결합하는 항체를 검사하는 방법으로, 이 반응은 최초에 기지항원, 피검혈청 및 보체를 혼합한다. 제2단계에서는 적혈구와 이것에 대응하는 용혈소의 혼합액을 가한다. 본 반응후 용혈이 일어나지 않으면 본체는 항원항체결합물에 결합한 것이 되어 양성이 되지만, 용혈이 일어난 경우 보체는 결합하지 않아 소비되지 않기 때문에 음성이 된다. 본 반응은 기지혈청을 써서 항원검출에 응용할 수 있으며, 마이코플라스마, 리케챠, 클라미디아, 바이러스, 매독 등의 진단에 쓰인다. |
||
| PLT | Primed Lymphocyte Typing |
|---|---|
| BlT | bleeding time; blood test; blood type, blood typing |
| BT | base of tongue; bedtime; bitemporal; bitrochanteric; bladder tumor; Blalock-Taussig [shunt]; bleedin... |
| HTC | hepatoma cell; hepatoma tissue culture; homozygous typing cell |
| PLT | pancreatic lymphocytic infiltration; platelet; primed lymphocyte test; primed lymphocyte typing; psi... |
| HTC | Homozygous Typing Cell |
|---|---|
| MLST | Multi Locus Sequence Typing |
| PLT | Primed Lymphocyte Typing |
| SBT | Sequence-based typing |
| SBT | Sequencing Based Typing |
| bacterial typing techniques | Procedures for identifying types and strains of bacteria. The most frequently employed typing systems are bacteriophage typing and serotyping as well as bacteriocin typing and biotyping. (12 Dec 1998) |
|---|---|
| bacteriophage typing | A technique of bacterial typing which differentiates between bacteria or strains of bacteria by their susceptibility to one or more bacteriophages. (12 Dec 1998) |
| phage typing | <microbiology> Bacteria may be typed by their susceptibility to a range of bacteriophages though confusion may arise if the bacteria carry plasmids encoding restriction endonucleases. (18 Nov 1997) |
| mycological typing techniques | Procedures for identifying types and strains of fungi. (12 Dec 1998) |
| HLA typing | <immunology> Tests done in order to determine if a patient has antibodies against a potential donor's HLA antigens. The presence of antibodies means that a particular graft will be rapidly rejected. (05 Mar 2000) |
| DNA typing | <molecular biology> See restriction fragment length polymorphism. (18 Nov 1997) |
| tissue typing | <procedure> The process of determining the allelic types of the antigens of the major histocompatibility complex (MHC) that determine whether a tissue graft will be accepted or rejected. at present carried out either by use of polyclonal or monoclonal antibodies against MHC antigens or less usually by tests of MHC restricted cell function or skin grafting (the latter not in humans). (18 Nov 1997) |
| typing | Classification according to type. Origin: see type Bacteriophage typing, a microbiological procedure, of epidemiological importance, for distinguishing types within a seemingly homogeneous bacterial species or strain by the use of type-specific bacteriophage. HLA typing, tests done in order to determine if a patient has antibodies against a potential donor's HLA antigens. The presence of antibodies means that a particular graft will be rapidly rejected. Also used to establish paternity and in forensic medicine. (05 Mar 2000) |
| male chromosome complement | The large majority of males have a 46, xy chromosome complement (46 chromosomes including an x and a y chromosome). A minority of males have other chromosome constitutions such as 47,xxy (47 chromosomes including two x chromosomes and a y chromosome) and 47,xyy (47 chromosomes including an x and two y chromosomes). (12 Dec 1998) |
| genetic complement | <biology, genetics> The set of chromosomes contained within any one particular cell. (07 May 1998) |
| receptors, complement | Molecules on the surface of some B-lymphocytes and macrophages, that recognise and combine with the c3b, c3d, c1q, and c4b components of complement. (12 Dec 1998) |
| receptors, complement 3b | Molecular sites on or in some B-lymphocytes and macrophages that recognise and combine with complement 3b. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. (12 Dec 1998) |
| receptors, complement 3d | Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognise and combine with complement 3d. Human cr2 serves as a receptor for both c3dg and the gp350/220 glycoprotein of herpes virus 4, human, and binds the monoclonal antibody okb7, which blocks binding of both ligands to the receptor. (12 Dec 1998) |
| chromosome complement | The whole set of chromosomes for the species. In humans, the chromosome complement (which is also called the karyotype) consists of 46 chromosomes. (12 Dec 1998) |
| complement | <immunology> A term originally used to refer to the heat labile factor in serum that causes immune cytolysis, the lysis of antibody coated cells and now referring to the entire functionally related system comprising at least 20 distinct serum proteins that is the effector not only of immune cytolysis but also of other biologic functions. Complement activation occurs by two different sequences, the classic and alternative pathways. The proteins of the classic pathway are termed components of complement and are designated by the symbols C1 through C9. C1 is a calcium dependent complex of three distinct proteins C1q, C1r and C1s. The proteins of the alternative pathway (collectively referred to as the properdin system) and complement regulatory proteins are known by semisystematic or trivial names. Fragments resulting from proteolytic cleavage of complement proteins are designated with lower case letter suffixes, for example, C3a. Inactivated fragments may be designated with the suffix i, for example C3bi. Activated components or complexes with biological activity are designated by a bar over the symbol for example C1 or C4b, 2a. The classic pathway is activated by the binding of C1 to classic pathway activators, primarily antigen-antibody complexes containing IgM, IgG1, IgG3, C1q binds to a single IgM molecule or two adjacent IgG molecules. The alternative pathway can be activated by IgA immune complexes and also by nonimmunologic materials including bacterial endotoxins, microbial polysaccharides and cell walls. Activation of the classic pathway triggers an enzymatic cascade involving C1, C4, C2 and C3, activation of the alternative pathway triggers a cascade involving C3 and factors B, D and P. Both result in the cleavage of C5 and the formation of the membrane attack complex. Complement activation also results in the formation of many biologically active complement fragments that act as anaphylatoxins, opsonins or chemotactic factors. (05 Jan 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|